2nd Gene Therapy for Blood Disorders
March 9 - May 11
There’s currently a lot of exciting news circulating about the progress of genetic therapies targeting blood disorders.
As more and more promising results emerge from various clinical 3 trials, it’s essential that this industry comes together to share knowledge, optimize trial design and discuss strategies for commercial launch.
The 2nd Gene Therapy for Blood Disorders is the only industry meeting specifically dedicated to overcoming the clinical and commercial challenges faced in gene therapy drug development for hemophilia, sickle cell disease, beta thalassemia and other blood disorders.
Join the likes of UniQure, Graphite Bio, bluebird bio, Sanofi, Spark Therapeutics and more industry pioneers as they share their latest insights and lessons learned to help accelerate programs to market.